Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas – – New data reinforce the ...

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor burden follicular ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

How Does Lunsumio Work for FL? Lunsumio is a special type of molecule that can attach to two different types of cells. This is called a bispecific antibody. It attaches to CD20 proteins on ...

Morningstar brands and products Company Portfolio ...

Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche, announced that it launched “Lunsumio for intravenous infusion 1 mg” and “Lunsumio for intravenous infusion 30 mg” (generic name: mosunetuzumab ...

Data showcase the benefits of fixed-duration Columvi (glofitamab-gxbm) and Lunsumio (mosunetuzumab-axgb) across different types of aggressive and indolent lymphomas. The company noted that long ...

Wednesday’s accelerated approval allows Epkinly to go toe to toe with Roche’s Lunsumio, which got its own third-line follicular lymphoma nod at the end of 2022. Both drugs are CD20xCD3 ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

(2024-12-09 | OTCQX:RHHBY) New and Updated Data for Genentech's Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma Stockhouse.com ...